The Center for International Blood and Marrow Transplant Research (CIBMTR) is a clinical research program dedicated to addressing important issues in the field of hematopoietic cell transplantation (HCT). CIBMTR maintains a large outcomes registry with information for more than 330,000 HCT recipients in over 300 centers and provides statistical support for analyzing those data. A separately funded Research Repository of donor-recipient specimens linked to these clinical data is available for a large subset of patients. Use of this Resource by hundreds of investigators around the world during the current and previous funding cycles have contributed to >700 publications on important issues and to improved global collaboration in data exchange and HCT research. With continuation of U24-CA76518, CIBMTR will continue to build on the infrastructure made possible by this support to facilitate in-depth exploration of clinical, immunogenetic, quality of life, and health services issues related to HCT. This application proposes to enhance this Resource and to advance its utility through the following Specific Aims: Resource Development: Provide the biomedical community a high-quality clinical database and state-of-the-art statistical support to address important issues in HCT and related fields through continued enhancement of data collection and management technology and procedures, expansion of the Resource to include patient-reported outcomes, gathering and disseminating data necessary for health services research and data on some non-HCT patients, development and application of novel statistical techniques, and collaboration with national and international networks in HCT and related fields. Resource Utilization: Increase use of data and statistical resources maintained by the CIBMTR to support studies with important clinical and policy implications, and enhance Working and Advisory Committee and Statistical Center processes to prioritize and complete these studies.
The CIBMTR continues to play a unique and important role in facilitating clinical research in HCT. It is committed to developing its research database and statistical capabilities to meet the needs of investigators in a rapidly evolving field. It will buld on the infrastructure made possible by support from U24-CA76518 and its partnerships to better serve the research and medical community and address important issues in HCT.
|Lund, Troy C; Ahn, Kwang Woo; Tecca, Heather R et al. (2018) Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. Biol Blood Marrow Transplant :|
|Nemecek, Eneida R; Hilger, Ralf A; Adams, Alexia et al. (2018) Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood Biol Blood Marrow Transplant 24:1651-1656|
|Rice, Carmel; Eikema, Dirk-Jan; Marsh, Judith C W et al. (2018) Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia. Biol Blood Marrow Transplant :|
|Petersdorf, Effie W; Stevenson, Philip; Malkki, Mari et al. (2018) Patient HLA Germline Variation and Transplant Survivorship. J Clin Oncol 36:2524-2531|
|Ustun, Celalettin; Young, Jo-Anne H; Papanicolaou, Genovefa A et al. (2018) Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant :|
|Scott, Emma C; Hari, Parameswaran; Kumar, Sathish et al. (2018) Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biol Blood Marrow Transplant 24:2443-2449|
|Robinson, Tara M; Fuchs, Ephraim J; Zhang, Mei-Jie et al. (2018) Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? Blood Adv 2:1180-1186|
|Inamoto, Yoshihiro; Valdés-Sanz, Nuria; Ogawa, Yoko et al. (2018) Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Biol Blood Marrow Transplant :|
|Woolfrey, Ann; Wang, Tao; Lee, Stephanie J et al. (2018) Donor-specific anti-HLA antibodies in unrelated hematopoietic cell transplantation for non-malignant disorders. Bone Marrow Transplant :|
|Gadalla, Shahinaz M; Wang, Tao; Loftus, David et al. (2018) No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia. Bone Marrow Transplant 53:383-391|
Showing the most recent 10 out of 641 publications